Sarepta Therapeutics’ (SRPT) Sell Rating Reiterated at HC Wainwright
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating reiterated by stock analysts at HC ...
BioSpace20h
6 Rare Diseases That Have New FDA-Approved Treatments
ITF, IntraBio and Orchard are among the companies that have won FDA nods in the past year for Duchenne muscular dystrophy, ...
Managed Healthcare Executive16h
Duchenne Muscular Dystrophy: The Brain Is Affected Too
Researchers, physicians, families and affected patients view Duchenne muscular dystrophy (DMD) as a neuromuscular condition. Children are diagnosed during the first years of life because they have ...
Oppenheimer Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)
In a report released today, Andreas Argyrides from Oppenheimer reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a ...